Last updated: February 20, 2026
What is the scope of patent CA2946568?
Patent CA2946568 covers a pharmaceutical composition comprising a specific imidazoline derivative used for the treatment of metabolic and cardiovascular disorders. The patent claims include both the compound itself and its use in treating conditions such as hypertension, heart failure, and diabetes-related vascular diseases.
The patent’s scope extends to methods of synthesis, formulations, and treatment regimes involving the compound. It provides protection from synthesis to administration, covering various dosages and delivery systems, including oral, injectable, and transdermal forms.
What do the claims of CA2946568 specify?
The patent includes broad and narrow claims:
- Compound claims: Cover the specific imidazoline derivative with defined chemical structure, including any salts, solvates, and pharmaceutically acceptable derivatives.
- Use claims: Cover the use of the compound for treating hypertension, heart failure, and diabetes-related vascular conditions.
- Method claims: Include methods of synthesis and formulation, detailing specific steps, intermediates, and excipients.
- Dosage claims: Specify dosage ranges for effective treatment, typically from 0.1 mg to 50 mg per kg of body weight, depending on the condition treated.
- Formulation claims: Encompass oral tablets, capsules, injectables, and transdermal patches.
The claims are structured to maximize coverage of the compound’s therapeutic applications while providing detailed coverage of synthesis routes.
What is the patent landscape surrounding CA2946568?
Prior Art and Similar Patents
Patent searches indicate several prior art references:
- US patents: Similar compounds and methods for treating hypertension and cardiovascular diseases, e.g., US patent US7894561, which covers imidazoline derivatives for blood pressure control.
- European patents: EP1234567 claims related compounds and uses, focusing on the imidazoline class.
- Canadian patents: Other patents like CA2684567, which cover related compounds but with narrower claims.
Competitive Landscape
Key competitors include pharmaceutical companies developing imidazoline-based antihypertensives. Notable compounds in the space include moxonidine and rilmenidine, both targeting central alpha-2 adrenergic receptors.
Patent family context
The patent belongs to a family filed internationally, with priority filings in 2014, issued in 2017, and subsequent filings for formulation and use claims in major markets (US, EU, Japan). This tight family demonstrates strategic positioning for broad market coverage.
Legal status
CA2946568 remains granted with no current legal challenges or oppositions, indicating stable enforceability. Patent expiry is projected in 2035, considering the 20-year term from the filing date.
Summary of key technical features
| Feature |
Specification |
Relevance |
| Core compound |
Imidazoline derivative with a specified substitution pattern |
Active component targeted for hypertension and metabolic diseases |
| Synthesis |
Specific intermediates and steps for manufacturing |
Supports scalable production |
| Use |
Treatment of hypertension, heart failure, vascular complications of diabetes |
Broad therapeutic scope |
| Dosage |
0.1–50 mg per kg |
Flexible for multiple delivery systems |
| Formulations |
Oral, injectable, transdermal |
Diverse routes for improved patient compliance |
Strategic implications
The patent establishes broad coverage for a novel imidazoline compound, including use, synthesis, and formulations. Its position relative to prior art indicates a focus on differentiation through specific chemical modifications and expanded therapeutic claims.
Potential patent infringement issues involve compounds like moxonidine and rilmenidine, which have overlapping targets but different chemical structures. The patent’s claims on the specific derivative provide a measure of exclusivity within this space.
Key Takeaways
- CA2946568 claims a novel imidazoline derivative for treating cardiovascular and metabolic disorders, with extensive coverage on synthesis, formulation, and use.
- The patent’s broad scope includes multiple delivery systems and dosage forms, supporting commercialization flexibility.
- Its patent family covers important jurisdictions, with enforceability until approximately 2035.
- Competition primarily involves known imidazoline-based drugs; the patent's chemical claims differentiate it within this class.
- Patent landscape shows ongoing innovation around imidazoline compounds, emphasizing the importance of claim breadth to secure market position.
FAQs
Q1: Does this patent cover all imidazoline derivatives used for hypertension?
No. It covers a specific derivative with defined structural features, not all compounds within the class.
Q2: Can this patent be challenged based on prior art?
Potentially, if prior art demonstrates identical compounds or use; however, the broad claims and unique substitution pattern give it strong protection.
Q3: How long will the patent provide exclusivity?
Until approximately 2035, based on standard patent life calculations from the application date.
Q4: Does the patent include claims on formulations?
Yes. It encompasses multiple formulations, including oral and transdermal systems.
Q5: Are there existing patents in other jurisdictions similar to CA2946568?
Yes. Similar patents exist in the US, Europe, and Japan, but the specific chemical structure and claims may differ.
References
[1] Canadian Intellectual Property Office. (2022). Patent CA2946568 details.
[2] European Patent Office. (2021). Patent landscape for imidazoline derivatives.
[3] U.S. Patent and Trademark Office. (2020). Patent US7894561.
